List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/744088/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients. Clinical Gastroenterology and Hepatology, 2022, 20, 162-172.e9.	4.4	113
2	SARSâ€CoVâ€2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease. United European Gastroenterology Journal, 2022, 10, 319-329.	3.8	27
3	Inversed Ratio of CD39/CD73 Expression on γî´T Cells in HIV Versus Healthy Controls Correlates With Immune Activation and Disease Progression. Frontiers in Immunology, 2022, 13, 867167.	4.8	3
4	Development of Antibody and Nanobody Tools for P2X7. Methods in Molecular Biology, 2022, , 99-127.	0.9	3
5	Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell–Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 2021, 73, e4020-e4024.	5.8	47
6	Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients. Journal of Neurology, 2021, 268, 5-7.	3.6	24
7	Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. Journal of Hepatology, 2021, 74, 312-320.	3.7	31
8	B cell analysis in SARS-CoV-2 versus malaria: Increased frequencies of plasmablasts and atypical memory B cells in COVID-19. Journal of Leukocyte Biology, 2021, 109, 77-90.	3.3	46
9	ADP-Ribosylation Regulates the Signaling Function of IFN-Î ³ . Frontiers in Immunology, 2021, 12, 642545.	4.8	7
10	A simple, sensitive, and lowâ€cost FACS assay for detecting antibodies against the native SARSâ€CoVâ€2 spike protein. Immunity, Inflammation and Disease, 2021, 9, 905-917.	2.7	5
11	Nanobodies as probes to investigate purinergic signaling. Biochemical Pharmacology, 2021, 187, 114394.	4.4	5
12	Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19. IScience, 2021, 24, 102752.	4.1	9
13	Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells. Frontiers in Immunology, 2021, 12, 703574.	4.8	5
14	Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD+ Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells. Cancers, 2021, 13, 76.	3.7	14
15	Blockade of Tigit on AML-Derived M2 Macrophages Results in Reprograming into the M1 Phenotype and Enhances CD47-Mediated Phagocytosis. Blood, 2021, 138, 3351-3351.	1.4	1
16	Evaluation of P2X7 Receptor Function in Tumor Contexts Using rAAV Vector and Nanobodies (AAVnano). Frontiers in Oncology, 2020, 10, 1699.	2.8	11
17	Decreased Frequency of Intestinal CD39+ î³î′+ T Cells With Tissue-Resident Memory Phenotype in Inflammatory Bowel Disease. Frontiers in Immunology, 2020, 11, 567472.	4.8	10
18	Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73- Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes. Cells, 2020, 9, 1750.	4.1	48

#	Article	IF	CITATIONS
19	Significance of Anti-Nuclear Antibodies and Cryoglobulins in Patients with Acute and Chronic HEV Infection. Pathogens, 2020, 9, 755.	2.8	7
20	Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Theranostics, 2020, 10, 2645-2658.	10.0	17
21	Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs). Cells, 2020, 9, 321.	4.1	46
22	Using FRET-Based Fluorescent Sensors to Monitor Cytosolic and Membrane-Proximal Extracellular ATP Levels. Methods in Molecular Biology, 2020, 2041, 223-231.	0.9	1
23	Flow Cytometry of Membrane Purinoreceptors. Methods in Molecular Biology, 2020, 2041, 117-136.	0.9	0
24	Generation and Function of Non-cell-bound CD73 in Inflammation. Frontiers in Immunology, 2019, 10, 1729.	4.8	43
25	Off-label application of intravenous immunoglobulin (IVIG) for treatment of Cogan's syndrome during pregnancy. BMJ Case Reports, 2019, 12, e227917.	0.5	5
26	Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors. Molecular Therapy - Methods and Clinical Development, 2019, 15, 211-220.	4.1	53
27	Novel biologics targeting the P2X7 ion channel. Current Opinion in Pharmacology, 2019, 47, 110-118.	3.5	33
28	P2X7-mediated ATP secretion is accompanied by depletion of cytosolic ATP. Purinergic Signalling, 2019, 15, 155-166.	2.2	13
29	CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells. Frontiers in Immunology, 2018, 9, 2553.	4.8	35
30	CD39 is upregulated during activation of mouse and human T cells and attenuates the immune response to Listeria monocytogenes. PLoS ONE, 2018, 13, e0197151.	2.5	49
31	Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity. Frontiers in Pharmacology, 2018, 9, 266.	3.5	25
32	A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation. Frontiers in Immunology, 2018, 8, 1989.	4.8	26
33	Monitoring Expression and Enzyme Activity of Ecto-ARTCs. Methods in Molecular Biology, 2018, 1813, 167-186.	0.9	3
34	Monitoring the Sensitivity of T Cell Populations Towards NAD+ Released During Cell Preparation. Methods in Molecular Biology, 2018, 1813, 317-326.	0.9	2
35	Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression. Journal of Leukocyte Biology, 2017, 101, 1263-1271.	3.3	30
36	Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo. Scientific Reports, 2017, 7, 14289.	3.3	55

#	Article	IF	CITATIONS
37	Ecto-ADP-ribosyltransferase ARTC2.1 functionally modulates FcγR1 and FcγR2B on murine microglia. Scientific Reports, 2017, 7, 16477.	3.3	12
38	Neutrophil Extracellular Traps Contain Selected Antigens of Anti-Neutrophil Cytoplasmic Antibodies. Frontiers in Immunology, 2017, 8, 439.	4.8	42
39	Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation. Science Translational Medicine, 2016, 8, 366ra162.	12.4	139
40	The Multiple Roles of ATP-Gated P2(X) Ion Channels in T Lymphocytes. Messenger (Los Angeles, Calif:) Tj ETQq0 (0 rgBT /C	overlock 10 T
41	Tuning IL-2 signaling by ADP-ribosylation of CD25. Scientific Reports, 2015, 5, 8959.	3.3	20
42	Molecular imaging of tumors with nanobodies and antibodies: Timing and dosage are crucial factors for improved <i>in vivo</i> detection. Contrast Media and Molecular Imaging, 2015, 10, 367-378.	0.8	43
43	P2X7 on Mouse T Cells: One Channel, Many Functions. Frontiers in Immunology, 2015, 6, 204.	4.8	93
44	Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDT. Scientific Reports, 2015, 5, 7850.	3.3	55
45	The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation. Journal of Autoimmunity, 2015, 58, 12-20.	6.5	68
46	Nucleotide-Induced Membrane-Proximal Proteolysis Controls the Substrate Specificity of T Cell Ecto–ADP-Ribosyltransferase ARTC2.2. Journal of Immunology, 2015, 195, 2057-2066.	0.8	17
47	<i>In vivo</i> nearâ€infrared fluorescence targeting of T cells: comparison of nanobodies and conventional monoclonal antibodies. Contrast Media and Molecular Imaging, 2014, 9, 135-142.	0.8	37
48	ADP-Ribosylation of P2X7: A Matter of Life and Death for Regulatory T Cells and Natural Killer T Cells. Current Topics in Microbiology and Immunology, 2014, 384, 107-126.	1.1	40
49	Identification and Analysis of ADP-Ribosylated Proteins. Current Topics in Microbiology and Immunology, 2014, 384, 33-50.	1.1	10
50	The art of blocking <scp>ADP</scp> â€ribosyltransferases (<scp>ART</scp> s): Nanobodies as experimental and therapeutic tools to block mammalian and toxin <scp>ART</scp> s. FEBS Journal, 2013,	4.7	8

50	experimental and therapeutic tools to block mammalian and toxin <scp>ART</scp> s. FEBS Journal, 2013, 280, 3543-3550.	4.7	8
51	<scp>CD</scp> 8â€Î² <scp>ADP</scp> â€ribosylation affects <scp>CD</scp> 8 ⁺ <scp>T</scp> â€cell function. European Journal of Immunology, 2013, 43, 1828-1838.	2.9	24
52	Technical Advance: A new cell preparation strategy that greatly improves the yield of vital and functional Tregs and NKT cells. Journal of Leukocyte Biology, 2013, 95, 543-549.	3.3	48
53	Extracellular NAD+: a danger signal hindering regulatory T cells. Microbes and Infection, 2012, 14, 1284-1292.	1.9	54
54	Alternative Splicing of the N-Terminal Cytosolic and Transmembrane Domains of P2X7 Controls Gating of the Ion Channel by ADP-Ribosylation. PLoS ONE, 2012, 7, e41269.	2.5	50

4

#	Article	IF	CITATIONS
55	Monoclonal Antibodies for the Identification and Purification of vNAR Domains and IgNAR Immunoglobulins from the Horn Shark <i>Heterodontus francisci</i> . Hybridoma, 2011, 30, 323-329.	0.4	9
56	Singleâ€domain llama antibodies as specific intracellular inhibitors of SpvB, the actin ADPâ€ribosylating toxin of <i>Salmonella typhimurium</i> . FASEB Journal, 2011, 25, 526-534.	0.5	35
57	Transgenic overexpression of toxin-related ecto-ADP-ribosyltransferase ART2.2 sensitizes T cells but not B cells to NAD-induced cell death. Molecular Immunology, 2011, 48, 1762-1770.	2.2	5
58	Strategies for the identification of arginine ADP-ribosylation sites. Journal of Proteomics, 2011, 75, 169-176.	2.4	16
59	Characterisation of a novel glycosylphosphatidylinositol-anchored mono-ADP-ribosyltransferase isoform in ovary cells. European Journal of Cell Biology, 2011, 90, 665-677.	3.6	7
60	Compartmentation of NAD ⁺ â€dependent signalling. FEBS Letters, 2011, 585, 1651-1656.	2.8	108
61	ADP-ribosylation of arginine. Amino Acids, 2011, 41, 257-269.	2.7	110
62	Analysis of Spontaneous Vs. Vaccine-Induced Antibody Responses Against Cancer-Testis Antigen MAGE-A3 in Cancer Patients. Blood, 2011, 118, 5087-5087.	1.4	0
63	Quantitative Magnetic Resonance Imaging of Enzyme Activity on the Cell Surface: In Vitro and In Vivo Monitoring of ADP-Ribosyltransferase 2 on T Cells. Molecular Imaging, 2010, 9, 7290.2010.00017.	1.4	10
64	Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2–P2X7 pathway. Journal of Experimental Medicine, 2010, 207, 2561-2568.	8.5	165
65	NAD+ and ATP Released from Injured Cells Induce P2X7-Dependent Shedding of CD62L and Externalization of Phosphatidylserine by Murine T Cells. Journal of Immunology, 2009, 182, 2898-2908.	0.8	116
66	Differential Regulation of P2X7 Receptor Activation by Extracellular Nicotinamide Adenine Dinucleotide and Ecto-ADP-Ribosyltransferases in Murine Macrophages and T Cells. Journal of Immunology, 2009, 183, 578-592.	0.8	51
67	Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Medical Microbiology and Immunology, 2009, 198, 157-174.	4.8	421
68	Characterisation of the R276A gain-of-function mutation in the ectodomain of murine P2X7. Purinergic Signalling, 2009, 5, 151-161.	2.2	12
69	Activation of the P2X7 ion channel by soluble and covalently bound ligands. Purinergic Signalling, 2009, 5, 139-149.	2.2	36
70	Basal and inducible expression of the thiol-sensitive ART2.1 ecto-ADP-ribosyltransferase in myeloid and lymphoid leukocytes. Purinergic Signalling, 2009, 5, 369-383.	2.2	20
71	The family of toxin-related ecto-ADP-ribosyltransferases in humans and the mouse. Protein Science, 2009, 11, 1657-1670.	7.6	147
72	Emerging Roles of NAD ⁺ and Its Metabolites in Cell SignalingA report on the NAD2008 symposium, Hamburg, Germany, 14 to 17 September 2008 Science Signaling, 2009, 2, mr1.	3.6	71

#	Article	IF	CITATIONS
73	Longitudinal and Functional Analysis of Spontaneous NY-ESO-1-Specific Antibody Responses in Multiple Myeloma Patients Blood, 2009, 114, 2831-2831.	1.4	0
74	High Sensitivity of Intestinal CD8+ T Cells to Nucleotides Indicates P2X7 as a Regulator for Intestinal T Cell Responses. Journal of Immunology, 2008, 181, 3861-3869.	0.8	48
75	ADPâ€ribosylation at R125 gates the P2X7 ion channel by presenting a covalent ligand to its nucleotide binding site. FASEB Journal, 2008, 22, 861-869.	0.5	116
76	Mammalian ADP-ribosyltransferases and ADP-ribosylhydrolases. Frontiers in Bioscience - Landmark, 2008, Volume, 6716.	3.0	91
77	Lipopolysaccharide, IFN-γ, and IFN-β Induce Expression of the Thiol-Sensitive ART2.1 Ecto-ADP-Ribosyltransferase in Murine Macrophages. Journal of Immunology, 2007, 179, 6215-6227.	0.8	29
78	Single domain antibodies from llama effectively and specifically block T cell ectoâ€ADPâ€ribosyltransferase ART2.2 in vivo. FASEB Journal, 2007, 21, 3490-3498.	0.5	106
79	NAD+ Released during Inflammation Participates in T Cell Homeostasis by Inducing ART2-Mediated Death of Naive T Cells In Vivo. Journal of Immunology, 2007, 179, 186-194.	0.8	135
80	Extracellular NAD and ATP: Partners in immune cell modulation. Purinergic Signalling, 2007, 3, 71-81.	2.2	152
81	Monitoring the expression of purinoceptors and nucleotide-metabolizing ecto-enzymes with antibodies directed against proteins in native conformation. Purinergic Signalling, 2007, 3, 359-366.	2.2	25
82	ADPâ€ribosylation of membrane proteins: Unveiling the secrets of a crucial regulatory mechanism in mammalian cells. Annals of Medicine, 2006, 38, 188-199.	3.8	42
83	The structure of human ADP-ribosylhydrolase 3 (ARH3) provides insights into the reversibility of protein ADP-ribosylation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15026-15031.	7.1	104
84	Targeted Disruption of CD38 Accelerates Autoimmune Diabetes in NOD/Lt Mice by Enhancing Autoimmunity in an ADP-Ribosyltransferase 2-Dependent Fashion. Journal of Immunology, 2006, 176, 4590-4599.	0.8	65
85	Activity and specificity of toxin-related mouse T cell ecto–ADP-ribosyltransferase ART2.2 depends on its association with lipid rafts. Blood, 2005, 105, 3663-3670.	1.4	56
86	A panel of monoclonal antibodies recognizing GPI-anchored ADP-ribosyltransferase ART4, the carrier of the Dombrock blood group antigens. Cellular Immunology, 2005, 236, 59-65.	3.0	25
87	Probing the expression and function of the P2X7 purinoceptor with antibodies raised by genetic immunization. Cellular Immunology, 2005, 236, 72-77.	3.0	26
88	Use of genetic immunization to raise antibodies recognizing toxin-related cell surface ADP-ribosyltransferases in native conformation. Cellular Immunology, 2005, 236, 66-71.	3.0	35
89	In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics, 2005, 6, 139.	2.8	224
90	Characterization of multiple alleles of the T-cell differentiation marker ART2 (RT6) in inbred and wild rats. Immunogenetics, 2005, 57, 739-749.	2.4	1

#	Article	IF	CITATIONS
91	CD38 Controls ADP-Ribosyltransferase-2-Catalyzed ADP-Ribosylation of T Cell Surface Proteins. Journal of Immunology, 2005, 174, 3298-3305.	0.8	87
92	Ecto-ADP-Ribosyltransferases (ARTs): Emerging Actors in Cell Communication and Signaling. Current Medicinal Chemistry, 2004, 11, 857-872.	2.4	109
93	T-Cell Survival Regulator LKLF Is Not Involved in Inappropriate Apoptosis of Diabetes-Prone BBDP Rat T Cells. Annals of the New York Academy of Sciences, 2003, 1010, 548-551.	3.8	4
94	Flow cytometric and immunoblot assays for cell surface ADP-ribosylation using a monoclonal antibody specific for ethenoadenosine. Analytical Biochemistry, 2003, 314, 108-115.	2.4	45
95	NAD-Induced T Cell Death. Immunity, 2003, 19, 571-582.	14.3	297
96	Cutting Edge: A Natural P451L Mutation in the Cytoplasmic Domain Impairs the Function of the Mouse P2X7 Receptor. Journal of Immunology, 2002, 169, 4108-4112.	0.8	184
97	Generation and Characterization of Ecto-ADP-Ribosyltransferase ART2.1/ART2.2-Deficient Mice. Molecular and Cellular Biology, 2002, 22, 7535-7542.	2.3	51
98	Mono-ADP-ribosyltransferases in human monocytes: regulation by lipopolysaccharide. Biochemical Journal, 2002, 362, 717.	3.7	21
99	Mono-ADP-ribosyltransferases in human monocytes: regulation by lipopolysaccharide. Biochemical Journal, 2002, 362, 717-723.	3.7	28
100	Structure of the Ecto-ADP-ribosyl Transferase ART2.2 from Rat. Journal of Molecular Biology, 2002, 322, 687-696.	4.2	52
101	T Cells of Different Developmental Stages Differ in Sensitivity to Apoptosis Induced by Extracellular NAD. Autoimmunity, 2002, 9, 197-202.	0.6	18
102	ADP-ribosyltransferases: plastic tools for inactivating protein and small molecular weight targets. Journal of Biotechnology, 2001, 92, 81-87.	3.8	26
103	Structure, chromosomal localization, and expression of the gene for mouse ecto-mono(ADP-ribosyl)transferase ART5. Gene, 2001, 275, 267-277.	2.2	35
104	The best defense is a good offense – Salmonella deploys an ADP-ribosylating toxin: Response. Trends in Microbiology, 2001, 9, 4-5.	7.7	5
105	DNA methylation contributes to tissue- and allele-specific expression of the T-cell differentiation marker RT6. Immunogenetics, 2001, 52, 231-241.	2.4	18
106	Actin is ADP-ribosylated by the Salmonella enterica virulence-associated protein SpvB. Molecular Microbiology, 2001, 39, 606-619.	2.5	106
107	The RT6 system of the rat: developmental, molecular and functional aspects. Immunological Reviews, 2001, 184, 96-108.	6.0	12
108	Rapid Induction of Naive T Cell Apoptosis by Ecto-Nicotinamide Adenine Dinucleotide: Requirement for Mono(ADP-Ribosyl)Transferase 2 and a Downstream Effector. Journal of Immunology, 2001, 167, 196-203.	0.8	59

#	Article	IF	CITATIONS
109	The spvB gene-product of the Salmonella enterica virulence plasmid is a mono(ADP-ribosyl)transferase. Molecular Microbiology, 2000, 37, 1106-1115.	2.5	88
110	Metalloprotease-Mediated Shedding of Enzymatically Active Mouse ecto-ADP-ribosyltransferase ART2.2 Upon T Cell Activation. Journal of Immunology, 2000, 165, 4463-4469.	0.8	58
111	Molecular characterization and expression of the gene for mouse NAD+:arginine ecto-mono(ADP-ribosyl)transferase, Art1. Biochemical Journal, 1998, 336, 561-568.	3.7	23
112	Use of the EST Database Resource to Identify and Clone Novel Mono(ADP-Ribosyl)Transferase Gene Family Members. Advances in Experimental Medicine and Biology, 1997, 419, 163-168.	1.6	12
113	Two Novel Human Members of an Emerging Mammalian Gene Family Related to Mono-ADP-Ribosylating Bacterial Toxins. Genomics, 1997, 39, 370-376.	2.9	61
114	Mono(Adp-Ribosyl)Transferases and Related Enzymes in Animal Tissues. Advances in Experimental Medicine and Biology, 1997, 419, 1-13.	1.6	60
115	Expression and Comparative Analysis of Recombinant Rat and Mouse RT6 T Cell Mono(ADP-Ribosyl)Transferases In E. Coli. Advances in Experimental Medicine and Biology, 1997, 419, 175-180.	1.6	11
116	Uncovered: the family relationship of a T-cell-membrane protein and bacterial toxins. Trends in Immunology, 1996, 17, 402-405.	7.5	38
117	Mouse T Cell Membrane Proteins Rt6â^'1 and Rt6â^'2 Are Arginine/Protein Mono(ADPribosyl)transferases and Share Secondary Structure Motifs with ADP-ribosylating Bacterial Toxins. Journal of Biological Chemistry, 1996, 271, 7686-7693.	3.4	127
118	Both allelic forms of the rat T cell differentiation marker RT6 display nicotinamide adenine dinucleotide (NAD)-glycohydrolase activity, yet only RT6.2 is capable of automodification upon incubation with NAD. European Journal of Immunology, 1995, 25, 2355-2361.	2.9	71
119	Premature Stop Codons Inactivate the RT6 Genes of the Human and Chimpanzee Species. Journal of Molecular Biology, 1994, 243, 537-546.	4.2	77
120	Loss of Rt6 Message and Most Circulating T Cells after Thymectomy of Diabetes Prone BB Rats. Autoimmunity, 1994, 18, 15-22.	2.6	14